68
Participants
Start Date
April 21, 2014
Primary Completion Date
May 7, 2018
Study Completion Date
May 7, 2018
RO6839921
Non-escalating IV doses given on Days 1-5 of Cycle 1.
RO6839921
Escalating IV doses of RO6839921 in solid tumor patients. Dose escalation will be calculated using the new Continual Reassessment Method (nCRM). RO6839921 will be given on Days 1-5 of 28-day cycles. Treatment will continue until disease progression, unacceptable toxicity or study discontinuation.
RO6839921
Escalating IV doses of RO6839921 in AML patients. Escalation will follow an adapted rolling 6 design. Starting dose \</= dose inducing Grade 2 toxicity in patients with solid tumors. RO6839921 will be given on Days 1-5 of 28-day cycles. Treatment will continue until disease progression, unacceptable toxicity or study discontinuation.
Medical University of South Carolina; Hollings Cancer Center, Charleston
Washington University, St Louis
University of Colorado, Aurora
University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto
Jewish General Hospital / McGill University, Montreal
Hoffmann-La Roche
INDUSTRY